UNSPSC 51111655: Rubitecan

This classification denotes a camptothecin analogue with the molecular formula C20H15N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H19C446XXB, chemically known as 4-ethyl-4-hydroxy-9-nitro-1h-pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione but generally known as rubitecan, which bears US NIH Compound Identifier 123613. European Medicines Agency schedules Rubitecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33089.

UNSPSC 51111655 Rubitecan is a Commodity-tier code for the anticancer drug rubitecan, a topoisomerase I inhibitor used in chemotherapy regimens. State and local governments procure rubitecan primarily through health departments, public hospital systems, and correctional health services for inpatient and outpatient oncology programs. The drug is typically sourced through group purchasing organizations, state pharmaceutical contracts, or direct vendor agreements that negotiate pricing and supply terms for formulary inclusion.

The source provided contains no recent state or local contract opportunities tagged to this code, making it impossible to characterize current issuing-body concentration, geographic activity, or representative solicitations. Rubitecan procurement at the state and local level generally follows established pharmaceutical-distribution channels and formulary processes rather than formal competitive solicitations visible in public notice systems, which may explain the absence of recent RFP, RFQ, or ITB records under this specific code.